BiomX Inc. (PHGE-UN)
ARCA ARCA Primary Summary
BiomX Inc. (PHGE-UN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has BiomX Inc. ever had a stock split?
BiomX Inc. Profile
| Biotechnology Industry | Healthcare Sector | Michael Oster CEO | ARCA Exchange | 09090D103 CUSIP |
| US Country | 20 Employees | - Last Dividend | - Last Split | 13 Mar 2019 IPO Date |
Overview
BiomX Inc. is a pioneering clinical-stage microbiome company focused on the development of innovative products by harnessing natural and engineered phage technologies. These technologies are uniquely designed to selectively eliminate harmful bacteria, targeting various health conditions that influence skin appearance and chronic diseases. Such diseases include inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). Founded in 2015 and located in Ness Ziona, Israel, BiomX leverages phage therapy in its quest to address critical unmet medical needs.
Products and Services
BiomX Inc.'s product pipeline features several innovative approaches towards treating bacterial-related health issues, emphasizing the importance of phage therapies in modern biotechnological applications:
- BX004:
- BX005:
- Colorectal Cancer Program:
A clinical-stage phage therapy specifically developed for cystic fibrosis (CF) patients who are battling chronic infections caused by Pseudomonas aeruginosa. Currently, BX004 has reached Phase 1b/2a clinical trials, showcasing BiomX’s commitment to providing solutions for respiratory infections affliction CF patients.
This product is a topical phage cocktail in Phase 1/2 clinical study aimed at targeting and killing Staphylococcus aureus (S. aureus), a significant bacterium associated with triggering and exacerbating the symptoms of skin diseases. Its formulation stands on the frontline of addressing skin-related bacterial infections through the strategic application of phage therapy.
BiomX is also involved in a colorectal cancer program emphasizing the utilization of engineered phages carrying various therapeutic payloads. These are administered intravenously to specifically target the Fusobacterium nucleatum bacteria found within the tumor microenvironment. This innovative approach represents a novel method in the fight against colorectal cancer, aiming to exploit the bacteria-tumor relationship for therapeutic benefit.
